top of page
  • Completed

NCT04671251: Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma

Updated: Aug 9, 2022

NCT04671251: Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma


AEVI 007

Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma


This is a multicenter, open-label, dose-escalation Phase 1b study of AEVI-007 in subjects with relapsed or refractory Multiple Myeloma.


The objectives of the study are to evaluate the safety, pharmacokinetics and pharmacodynamics of AEVI-007.


Sponsor

Avalo Therapeutics, Inc.


Multiple Locations

 

ClinicalTrials.gov Identifier: NCT04671251


Official Title: A Multicenter, Open-Label, Dose-Escalation Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma


First Posted : December 17, 2020


Click here to see details on ClinicalTrials.gov

 

Drug: AEVI-007

AEVI-007

Anti-IL-18 Monoclonal Antibody CERC-007

CERC 007

CERC-007

CERC007

MEDI2338


CERC-007 (formerly AEVI-007)

 

Locations

United States, California

United States, Florida

United States, Maryland

United States, North Carolina

United States, Wisconsin








Comments


Posts Archive
bottom of page